<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41876">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922024</url>
  </required_header>
  <id_info>
    <org_study_id>CURETIS US 001</org_study_id>
    <nct_id>NCT01922024</nct_id>
  </id_info>
  <brief_title>Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis UnyveroTM LRT Application</brief_title>
  <official_title>Detection of Microorganisms and Antibiotic Resistance Genes in Lower Respiratory Tract (LRT) Samples, Using the Curetis UnyveroTM LRT Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Curetis AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Curetis AG</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Curetis UnyveroTM LRT Application is intended to detect and to identify genes of 17
      microorganisms and 22 genes associated with antibiotic resistance in less than 4 hours.

      In this study, the performance of the UnyveroTM LRT Application shall be tested under
      clinical conditions and compared to (1) a composite reference method (for non-atypical or
      cultured microorganisms) or (2) a molecular PCRbased reference method for the 3 atypical
      microorganisms Chlamydophila pneumoniae, Legionella pneumoniae, and Pneumocystis jirovecii,
      and for resistance genes.

      PCR amplifications are followed by bi-directional sequencing, including comparison of the
      test results Time to result will be compared for the UnyveroTM LRT Application and
      standard-of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, controlled, non-randomized multicenter clinical study that
      compares a new diagnostic device, the UnyveroTM LRT Application (based on molecular
      diagnostic methods) to either (1) a composite reference method (for non-atypical
      microorganisms), (2) a composite PCR-based method for 3 atypical microorganisms or (3) a
      PCR-based reference method for resistance genes.

      The study will use leftover lower respiratory tract samples taken from subjects suspected
      with lower respiratory tract infections: (a) Specimens taken prospectively for
      standard-of-care (i.e. microbiology testing) from hospitalized subjects. (b) Banked
      specimens for rare microorganisms.

      As the device is under investigation, the test results provided by the UnyveroTM LRT
      Application will not be made available to the treating physician and therefore will not be
      used for diagnosis, treatment or other management decisions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Clinical sensitivity and specificity for microorganism detection as compared to routine microbiology and other reference methods including PCR and sequencing</measure>
    <time_frame>up to 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity for microorganism detection will be determined against the respective reference method consisting of standard procedure and/or a reference method based on PCR and bi-directional sequencing using alternative primers. Sensitivity for non-atypical microorganism detection will thus be determined if at least 1 out of 2 reference methods have identified microorganisms that are covered by the panel of the investigational IVD. Results will further be analyzed against standard of-care alone, as well as against composite comparator. Sensitivity for atypical microorganism detection will be determined against PCR with alternative primers as reference method. Specificity for microorganism detection will be determined in all samples included in the trial. Individual specificities will be calculated for the detection of the respiratory microorganisms analyzed by the investigational IVD compared to the microorganisms reference method.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Tested Surplus Clinical Specimens</arm_group_label>
    <description>Patients with suspicion of lower respiratory tract infection (pneumonia)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tested Surplus Clinical Specimens</intervention_name>
    <description>Testing on the Unyvero(TM)instrument</description>
    <arm_group_label>Tested Surplus Clinical Specimens</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bronchial lavage Tracheal aspirate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Suspicion of lower respiratory tract infection in hospitalized subjects.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized subjects with suspicion of lower respiratory tract infection

          -  Age at least 18 years

          -  Available surplus respiratory aspirate or bronchial lavage sample

        Exclusion Criteria:

          -  Out-patient (ambulatory patient)

          -  Known infection with HIV, HBV or tuberculosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Thews, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Curetis AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90049</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Hindler</last_name>
      <phone>310-794-2749</phone>
      <email>JFHindler@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Romney Humphries, PhD., D(ABMM)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Qi, Ph.D.</last_name>
      <phone>312-926-2181</phone>
      <email>cqi451@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Wunderink, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Howard</last_name>
      <phone>410-955-6510</phone>
      <email>tross@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Carroll, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Cumming</last_name>
      <phone>248-435-4668</phone>
      <email>13089@beaumont.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Powell</last_name>
      <phone>248-435-4668</phone>
      <email>kimberly.powell@beaumont.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Sims, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lynch</last_name>
      <phone>507-266-4665</phone>
      <email>lynch.david@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Karaus</last_name>
      <phone>5075388472</phone>
      <email>karaus.mary@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robin Patel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore - LIJ Laboratories</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Korologos</last_name>
      <phone>516-719-1079</phone>
      <email>dkorolog@nshs.edu</email>
    </contact>
    <investigator>
      <last_name>Stephan Juretschko, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Vicino</last_name>
      <phone>585-275-1621</phone>
      <email>david_vicino@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Dwight Hardy, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Health System</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Hernandex</last_name>
      <phone>570-214-9367</phone>
      <email>drhernandez@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Donna Wolk, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Butler-Wu, Ph.D., D(ABMM)</last_name>
      <phone>206-598-5449</phone>
      <email>butlerwu@uw.ed</email>
    </contact>
    <investigator>
      <last_name>Susan Butler-Wu, Ph.D., D(ABMM)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
